# Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

> **NCT06696833** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 18 (estimated)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukemia, Adult

## Interventions

- **BIOLOGICAL:** QH10304-BAL-01
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06696833
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696833, "Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06696833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*